{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:14:49Z","timestamp":1789679689627,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11596-020-2181-5","type":"journal-article","created":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T06:02:17Z","timestamp":1587880937000},"page":"354-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Huai Qi Huang-induced Apoptosis via Down-regulating PRKCH and Inhibiting RAF\/MEK\/ERK Pathway in Ph+ Leukemia Cells"],"prefix":"10.1007","volume":"40","author":[{"given":"Wen-fu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-qing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-yan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-ming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,26]]},"reference":[{"issue":"7","key":"2181_CR1","first-page":"2049","volume":"60","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Vieira S, Mendiola R, et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res, 2000,60(7):2049\u20132055","journal-title":"Cancer Res"},{"issue":"10","key":"2181_CR2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res, 2010,34(10):1255\u20131268","journal-title":"Leuk Res"},{"issue":"5","key":"2181_CR3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","volume":"17","author":"N von Bubnoff","year":"2003","unstructured":"von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia, 2003,17(5):829-838","journal-title":"Leukemia"},{"issue":"4","key":"2181_CR4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","volume":"47","author":"P La Rosee","year":"2010","unstructured":"La Rosee P, Deininger MW. Resistance to imatinib: mutations and beyond. Semin Hematol, 2010,47(4):335-343","journal-title":"Semin Hematol"},{"issue":"8","key":"2181_CR5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/cncr.25690","volume":"117","author":"HJ Lee","year":"2011","unstructured":"Lee HJ, Thompson JE, Wang ES, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer, 2011,117(8):1583\u20131594","journal-title":"Cancer"},{"issue":"4","key":"2181_CR6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer, 2013, 21(4):1097\u20131103","journal-title":"Support Care Cancer"},{"issue":"22","key":"2181_CR7","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"Experts in Chronic Myeloid Leukemia.","year":"2013","unstructured":"Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013,121(22):4439\u20134442","journal-title":"Blood"},{"issue":"1","key":"2181_CR8","first-page":"199","volume":"46","author":"U Thatte","year":"2000","unstructured":"Thatte U, Bagadey S, Dahanukar S. Modulation of programmed cell death by medicinal plants. Cell Mol Biol (Noisy-le-grand), 2000,46(1):199\u2013214","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"7\u20138","key":"2181_CR9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1081\/CNV-120005926","volume":"20","author":"A Vickers","year":"2002","unstructured":"Vickers A. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest, 2002,20(7\u20138):1069\u20131079","journal-title":"Cancer Invest"},{"issue":"11","key":"2181_CR10","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/j.1349-7006.2010.01680.x","volume":"101","author":"N Zhang","year":"2010","unstructured":"Zhang N, Kong X, Yan S, et al. Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci, 2010,101(11):2375\u20132383","journal-title":"Cancer Sci"},{"issue":"1","key":"2181_CR11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3892\/or.2015.3950","volume":"34","author":"X Song","year":"2015","unstructured":"Song X, Li Y, Zhang H, et al. The anticancer effect of Huaier (Review). Oncol Rep, 2015,34(1):12\u201321","journal-title":"Oncol Rep"},{"issue":"11","key":"2181_CR12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/gutjnl-2018-315983","volume":"67","author":"Q Chen","year":"2018","unstructured":"Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018,67(11):2006\u20132016","journal-title":"Gut"},{"key":"2181_CR13","doi-asserted-by":"crossref","first-page":"115109","DOI":"10.1016\/j.carbpol.2019.115109","volume":"223","author":"L Fang","year":"2019","unstructured":"Fang L, Zhang Y, Zang Y, et al. HP-1 inhibits the progression of ccRCC and enhances sunitinib therapeutic effects by suppressing EMT. Carbohydr Polym, 2019, 223:115109","journal-title":"Carbohydr Polym"},{"key":"2181_CR14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.phrs.2018.04.010","volume":"132","author":"Y Ma","year":"2018","unstructured":"Ma Y, Wang C, Zhang Q, et al. The effects of polysaccharides from Auricularia auricula (Huaier) in adjuvant anti-gastrointestinal cancer therapy: A systematic review and network meta-analysis. Pharmacol Res, 2018,132:80\u201389","journal-title":"Pharmacol Res"},{"key":"2181_CR15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.carbpol.2016.06.046","volume":"151","author":"Z Luo","year":"2016","unstructured":"Luo Z, Hu X, Xiong H, et al. A polysaccharide from Huaier induced apoptosis in MCF-7 breast cancer cells via down-regulation of MTDH protein. Carbohydr Polym, 2016,151:1027\u20131033","journal-title":"Carbohydr Polym"},{"issue":"1","key":"2181_CR16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.carbpol.2012.09.006","volume":"92","author":"Y Sun","year":"2013","unstructured":"Sun Y, Sun T, Wang F, et al. A polysaccharide from the fungi of Huaier exhibits anti-tumor potential and immunomodulatory effects. Carbohydr Polym, 2013,92(1):577\u2013582","journal-title":"Carbohydr Polym"},{"issue":"7","key":"2181_CR17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.7150\/ijbs.27360","volume":"15","author":"B Hu","year":"2019","unstructured":"Hu B, Yan W, Wang M, et al. Huaier polysaccharide inhibits the stem-like characteristics of ERalpha-36(high) triple negative breast cancer cells via inactivation of the ERalpha-36 signaling pathway. Int J Biol Sci, 2019,15(7):1358\u20131367","journal-title":"Int J Biol Sci"},{"key":"2181_CR18","doi-asserted-by":"crossref","first-page":"109071","DOI":"10.1016\/j.biopha.2019.109071","volume":"117","author":"P Qu","year":"2019","unstructured":"Qu P, Han J, Qiu Y, et al. Huaier extract enhances the treatment efficacy of imatinib in Ik6(+) Ph(+) acute lymphoblastic leukemia. Biomed Pharmacother, 2019, 117:109071","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2181_CR19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41598-018-36940-w","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Lv H, Xu Z, et al. Huaier n-butanol extract suppresses proliferation and metastasis of gastric cancer via c-Myc-Bmi1 axis. Sci Rep, 2019,9(1):447","journal-title":"Sci Rep"},{"issue":"21","key":"2181_CR20","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.7150\/jca.25909","volume":"9","author":"Y Tao","year":"2018","unstructured":"Tao Y, Shan L, Xu X, et al. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Dow-nregulation of YAP in Hepatocellular Carcinoma. J Cancer, 2018,9(21):3962\u20133970","journal-title":"J Cancer"},{"issue":"6","key":"2181_CR21","volume":"37","year":"2017","unstructured":"Liang P, Peng S, Zhang M, et al. Huai Qi Huang corrects the balance of Th1\/Th2 and Treg\/Th17 in an ovalbumin-induced asthma mouse model. Biosci Rep, 2017,37(6). pii: BSR20171071","journal-title":"Biosci Rep"},{"issue":"3","key":"2181_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.17305\/bjbms.2016.887","volume":"16","author":"T Li","year":"2016","unstructured":"Li T, Mao J, Huang L, et al. Huaiqihuang may protect from proteinuria by resisting MPC5 podocyte damage via targeting p-ERK\/CHOP pathway. Bosn J Basic Med Sci, 2016,16(3):193\u2013200","journal-title":"Bosn J Basic Med Sci"},{"issue":"12","key":"2181_CR23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jfma.2013.10.019","volume":"112","author":"LT Li","year":"2013","unstructured":"Li LT, Shi MY, Wei SY, et al. Huai Qi Huang ameliorates proteinuria and hematuria in mild IgA nephropathy patients: a prospective randomized controlled study. J Formos Med Assoc, 2013,112(12):766\u2013772","journal-title":"J Formos Med Assoc"},{"issue":"9","key":"2181_CR24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3109\/0886022X.2014.952746","volume":"36","author":"SB Duan","year":"2014","unstructured":"Duan SB, Pan P, Xu Q, et al. Preliminary study of Huai Qi Huang granules delay the development of primary glomerular diseases in human. Ren Fail, 2014,36(9):1407\u20131410","journal-title":"Ren Fail"},{"issue":"4","key":"2181_CR25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11655-015-2293-0","volume":"23","author":"H Liu","year":"2017","unstructured":"Liu H, Sun W, Gu LB, et al. Huaiqihuang Granules () reduce proteinuria by enhancing nephrin expression and regulating necrosis factor kappaB signaling pathway in adriamycin-induced nephropathy. Chin J Integr Med, 2017,23(4):279\u2013287","journal-title":"Chin J Integr Med"},{"key":"2181_CR26","first-page":"8612190","volume":"2016","author":"J Pu","year":"2016","unstructured":"Pu J, Zhang Y, Zhou J. Effect of Huai Qi Huang on Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells through miR-200a. Evid Based Complement Alternat Med, 2016,2016:8612190","journal-title":"Evid Based Complement Alternat Med"},{"issue":"5","key":"2181_CR27","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1159\/000443119","volume":"38","author":"J Han","year":"2016","unstructured":"Han J, Lin M, Zhou D, et al. Huang Qi Huai Granules Induce Apoptosis in Acute Lymphoblastic Leukemia Cells through the Akt\/FoxO1 Pathway. Cell Physiol Biochem, 2016,38(5):1803\u20131814","journal-title":"Cell Physiol Biochem"},{"issue":"252","key":"2181_CR28","first-page":"121","volume":"6","author":"L Ma","year":"2014","unstructured":"Ma L, Shan Y, Bai R, et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med, 2014, 6(252):121r-252r","journal-title":"Sci Transl Med"},{"issue":"9","key":"2181_CR29","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood-2005-05-2103","volume":"107","author":"H Liu","year":"2006","unstructured":"Liu H, Zang C, Fenner MH, et al. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha\/gamma ligand TZD18. Blood, 2006,107(9):3683\u20133692","journal-title":"Blood"},{"issue":"139","key":"2181_CR30","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1126\/scisignal.3139re6","volume":"3","author":"J Colicelli","year":"2010","unstructured":"Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal, 2010,3(139):e6","journal-title":"Sci Signal"},{"issue":"2","key":"2181_CR31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, et al. JAK\/ STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 2004,18(2):189\u2013218","journal-title":"Leukemia"},{"key":"2181_CR32","first-page":"267","volume-title":"Hematology Am Soc Hematol Educ Program","author":"KJ Savage","year":"2005","unstructured":"Savage KJ. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program 2005:267\u2013277."},{"issue":"1","key":"2181_CR33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nm1524","volume":"13","author":"T Vilimas","year":"2007","unstructured":"Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med, 2007,13(1):70\u201377","journal-title":"Nat Med"},{"issue":"5","key":"2181_CR34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito P, Saborowski A, Yue J, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 2014,25(5):697\u2013710","journal-title":"Cancer Cell"},{"issue":"3","key":"2181_CR35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","volume":"11","author":"J Jing","year":"2012","unstructured":"Jing J, Greshock J, Holbrook JD, et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther, 2012,11(3):720\u2013729","journal-title":"Mol Cancer Ther"},{"key":"2181_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-016-0258-1","volume":"9","author":"JT Leonard","year":"2016","unstructured":"Leonard JT, Raess PW, Dunlap J, et al. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent. J Hematol Oncol, 2016,9:31","journal-title":"J Hematol Oncol"},{"issue":"26","key":"2181_CR37","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","volume":"124","author":"MR Burgess","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood, 2014,124(26):3947\u20133955","journal-title":"Blood"},{"issue":"9","key":"2181_CR38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ptr.2062","volume":"21","author":"J Yu","year":"2007","unstructured":"Yu J, Liu H, Lei J, et al. Antitumor activity of chloroform fraction of Scutellaria barbata and its active constituents. Phytother Res, 2007,21(9):817\u2013822","journal-title":"Phytother Res"},{"issue":"5","key":"2181_CR39","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.fct.2008.01.027","volume":"46","author":"L Harhaji","year":"2008","unstructured":"Harhaji L, Mijatovic S, Maksimovic-Ivanic D, et al. Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: in vitro and in vivo study. Food Chem Toxicol, 2008,46(5):1825-1833","journal-title":"Food Chem Toxicol"},{"issue":"7","key":"2181_CR40","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.fct.2011.02.008","volume":"49","author":"S Rashid","year":"2011","unstructured":"Rashid S, Unyayar A, Mazmanci MA, et al. A study of anti-cancer effects of Funalia trogii in vitro and in vivo. Food Chem Toxicol, 2011,49(7):1477\u20131483","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"2181_CR41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3892\/or.2015.3950","volume":"34","author":"X Song","year":"2015","unstructured":"Song X, Li Y, Zhang H, et al. The anticancer effect of Huaier (Review). Oncol Rep, 2015,34(1):12\u201321","journal-title":"Oncol Rep"},{"issue":"4","key":"2181_CR42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1023781114568","volume":"22","author":"KB Reddy","year":"2003","unstructured":"Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 2003,22(4):395\u2013403","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2181_CR43","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3892\/ijo.2015.3094","volume":"47","author":"L Yan","year":"2015","unstructured":"Yan L, Liu X, Yin A, et al. Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK\/p38 pathway. Int J Oncol, 2015,47(3):1054\u20131060","journal-title":"Int J Oncol"},{"issue":"4","key":"2181_CR44","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3892\/or.2012.1961","volume":"28","author":"X Wang","year":"2012","unstructured":"Wang X, Zhang N, Huo Q, et al. Anti-angiogenic and antitumor activities of Huaier aqueous extract. Oncol Rep, 2012,28(4):1167\u20131175","journal-title":"Oncol Rep"},{"issue":"23","key":"2181_CR45","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-15-0393","volume":"21","author":"MC Andrews","year":"2015","unstructured":"Andrews MC, Turner N, Boyd J, et al. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1\/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Clin Cancer Res, 2015,21(23):5222\u20135234","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2181_CR46","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2015-04-639138","volume":"126","author":"CL Jones","year":"2015","unstructured":"Jones CL, Gearheart CM, Fosmire S, et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood, 2015,126(19):2202\u20132212","journal-title":"Blood"},{"issue":"3","key":"2181_CR47","first-page":"e214078","volume":"14","author":"H Zhang","year":"2019","unstructured":"Zhang H, Gordon R, Li W, et al. Genistein treatment duration effects biomarkers of cell motility in human prostate. PLoS One, 2019,14(3):e214078","journal-title":"PLoS One"},{"issue":"7","key":"2181_CR48","doi-asserted-by":"crossref","first-page":"e102289","DOI":"10.1371\/journal.pone.0102289","volume":"9","author":"JM Pavese","year":"2014","unstructured":"Pavese JM, Ogden IM, Voll EA, et al. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One, 2014,9(7):e102289","journal-title":"PLoS One"},{"issue":"11","key":"2181_CR49","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1158\/0008-5472.CAN-06-0555","volume":"66","author":"SC Cunningham","year":"2006","unstructured":"Cunningham SC, Gallmeier E, Hucl T, et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res, 2006,66(11):5560\u20135564","journal-title":"Cancer Res"},{"issue":"16","key":"2181_CR50","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/jnci\/djp227","volume":"101","author":"L Xu","year":"2009","unstructured":"Xu L, Ding Y, Catalona WJ, et al. MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst, 2009,101(16):1141\u20131155","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2181_CR51","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest, 2011,121(1):396\u2013409","journal-title":"J Clin Invest"},{"issue":"6","key":"2181_CR52","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 2012,119(6):1501\u20131510","journal-title":"Blood"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-020-2181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-020-2181-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-020-2181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T23:50:49Z","timestamp":1619394649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-020-2181-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1007\/s11596-020-2181-5","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"26 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}